日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy

在 Sparsentan 治疗 IgA 肾病的 3 期 PROTECT 试验中,完全蛋白尿缓解与肾功能之间的关联

Heerspink, Hiddo J L; Rovin, Brad H; Komers, Radko; Hendry, Bruce; Mercer, Alex; Preciado, Priscila; Murphy, Edward; Tesar, Vladimir

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial

Sparsentan 对 DUPLEX 试验中入组的遗传相关性 FSGS 患者的抗蛋白尿作用

Yee, Jennifer; Gong, Wu; Inrig, Jula; Rheault, Michelle N; Gruber, Angela J; Bedard, Patricia W; Komers, Radko; Trachtman, Howard

Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis

蛋白尿作为局灶节段性肾小球硬化症临床试验的终点

Mariani, Laura H; Trachtman, Howard; Thompson, Aliza; Gillespie, Barbara S; Denburg, Michelle; Diva, Ulysses; Geetha, Duvuru; Greasley, Peter J; Hladunewich, Michelle A; Huizinga, Robert B; Inrig, Jula K; Komers, Radko; Laurin, Louis-Philippe; Little, Dustin J; Nachman, Patrick H; Smith, Kimberly A; Walsh, Liron; Gibson, Keisha L

Měnglà Virus VP40 Localizes to the Nucleus and Impedes the RIG-I Signaling Pathway

门格拉病毒VP40定位于细胞核并阻碍RIG-I信号通路

Sweeney Gibbons, Joyce; Thakur, Naveen; Komers, Emma; Vogel, Olivia A; Chakraborty, Poushali; Tufariello, JoAnn M; Basler, Christopher F

Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT study

IgA肾病中的稀疏烷:PROTECT研究出版物的简明语言摘要

Rovin, Brad H; Komers, Radko; Scroggins, Chris; Barratt, Jonathan

Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease

稀疏肽在肾脏中的保护机制:来自慢性肾脏病模型研究的启示

Kohan, Donald E; Bedard, Patricia W; Jenkinson, Celia; Hendry, Bruce; Komers, Radko

Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS

在FSGS小鼠模型中,Sparsentan可改善肾小球血流动力学、细胞功能和组织修复。

Georgina Gyarmati ,Urvi Nikhil Shroff ,Audrey Izuhara ,Sachin Deepak ,Radko Komers ,Patricia W Bedard ,Janos Peti-Peterdi

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

Sparsentan 3期DUPLEX研究中局灶节段性肾小球硬化症患者的基线特征

Trachtman, Howard; Radhakrishnan, Jai; Rheault, Michelle N; Alpers, Charles E; Barratt, Jonathan; Heerspink, Hiddo J L; Noronha, Irene L; Perkovic, Vlado; Rovin, Brad; Trimarchi, Hernán; Wong, Muh Geot; Mercer, Alex; Inrig, Jula; Rote, William; Murphy, Ed; Bedard, Patricia W; Roth, Sandra; Bieler, Stewart; Komers, Radko

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

Sparsentan治疗局灶节段性肾小球硬化症的DUET开放标签扩展研究:长期疗效和安全性

Campbell, Kirk N; Gesualdo, Loreto; Murphy, Edward; Rheault, Michelle N; Srivastava, Tarak; Tesar, Vladimir; Komers, Radko; Trachtman, Howard

Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy

在 IgA 肾病 gddY 小鼠模型中,Sparsentan 优于氯沙坦

Hajime Nagasawa, Seiji Ueda, Hitoshi Suzuki, Celia Jenkinson, Yusuke Fukao, Maiko Nakayama, Tomoyuki Otsuka, Teruyuki Okuma, Wilmelenne Clapper, Kai Liu, Mai Nguyen, Radko Komers, Yusuke Suzuki